The Daily Biotech Pulse: Novartis Snags Twin FDA Nods, Novavax Positive Vaccine News Continues, Arcutis Psoriasis Application Accepted For Review
Here's a roundup of top developments in the biotech space over the last 24 hours.
Verastem Oncology Q3 EPS $(0.07) Down From $0.11 YoY
Verastem Oncology (NASDAQ:VSTM) reported quarterly losses of $(0.07) per share. This is a 163.64 percent decrease over earnings of $0.11 per share from the same period last year.
Why Verastem Shares Are Trading Higher Today
Verastem Inc (NASDAQ: VSTM) is trading higher Monday after the company announced updated investigator-sponsored Phase 1/2 FRAME study data of VS-6766 with defactinib in low-grade serous ovarian cancer showing "encouraging response rates and progression-free survival."
35 Stocks Moving In Monday’s Mid-Day Session
Gainers
ZIVO Bioscience, Inc. (NASDAQ: ZIVO) jumped 145% to $6.86 after declining around 17% on Friday.
Verastem Oncology And Amgen Partner To Evaluate VS-6766 In Combination With LUMAKRASTM In Patients With KRAS G12C-Mutant Non-Small Cell Lung Cancer
Clinical Collaboration Will Assess Safety and Efficacy of More Complete Vertical Blockade Along RAS Pathway
Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients
24 Stocks Moving in Monday’s Pre-Market Session
Gainers
Verastem, Inc. (NASDAQ: VSTM) rose 30.8% to $3.61 in pre-market trading after the company announced a mini oral presentation highlighting updated data from the ongoing investigator-sponsored Phase 1/2 FRAME study.
Verastem Shares Are Trading Higher On Encouraging Combo Therapy Data At ESMO Presentation
Verastem Oncology Inc (NASDAQ:VSTM) stock is trading higher after updated data from the ongoing Phase 1/2 FRAME study. The investigator-sponsored study…
Verastem Oncology On Sunday Announces Updated Investigator-Sponsored Phase 1/2 FRAME Study Data Of VS-6766 With Defactinib In Low-Grade Serous Ovarian Cancer Showing Encouraging Response Rates And Progression-Free Survival Presented at ESMO 2021
Median progression-free survival (mPFS) across all patients treated with VS-6766 in combination with defactinib in the study is 23.0 months.
11 of 24 (46%) patients treated with the combination achieved a confirmed